John W. Smither - 27 Dec 2023 Form 4 Insider Report for Applied Molecular Transport Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 27 Dec 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Dec 2023, 17:38:19 UTC
Prior SEC filing: 14 Sep 2023
Next SEC filing: 29 Dec 2023
Source filing: View source filing
Reporting owner signature: /s/ Brandon Hants Attorney-in-Fact for John W. Smither

Key filing fact

John W. Smither filed Form 4 for Applied Molecular Transport Inc. on 28 Dec 2023.

Key facts

This page summarizes John W. Smither's Form 4 filing for Applied Molecular Transport Inc..
3 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 28 Dec 2023, 17:38.

Change

Previous filing in this sequence was filed on 14 Sep 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AMTI transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -60,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Dec 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 60,000
Exercise price: $8.01
Footnotes: F1

AMTI transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -20,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 24 May 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $3.13
Footnotes: F1

AMTI transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -20,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Dec 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $0.3400
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

John W. Smither is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger dated as of September 21, 2023 (the "Merger Agreement"), by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. and the Issuer, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing.

Footnote F2

Pursuant to the terms of the Merger Agreement, this option was exchanged for an option covering 2,662 shares of Cyclo Common Stock.